Citius Oncology grants Dutia 125K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Citius Oncology, Inc. (CTOR) director Suren G. Dutia received a grant of stock options covering 125,000 common shares on November 12, 2026, at an exercise price of $0.5223 per share. The report also lists a 300,000-share position represented by restricted stock units and existing options covering 125,000 shares at $1.07 per share and 150,000 shares at $2.15 per share.
Insider Trade Summary
Grant/Award: 125,000 shares
Grant/Award
1 txn
Insider
Dutia Suren G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 125,000 | $0.00 | $0.00 |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 400,000 options, with 275,000 underlying shares of Common Stock (Direct);
Common Stock — 300,000 shares (Direct)
Footnotes (4)
- F1. Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F4. These options are 100% vested.
Key Figures
Options granted: 125,000 options covering common shares
Exercise price: $0.5223 per share
Restricted stock units: 300,000 shares
+4 more
7 metrics
Options granted
125,000 options covering common shares
Granted November 12, 2026
Exercise price
$0.5223 per share
Options granted November 12, 2026
Restricted stock units
300,000 shares
Reported position; the units were granted September 19, 2025
Options underlying shares
125,000 shares
Exercise price $1.07 per share; expiration December 12, 2034
Exercise price
$1.07 per share
Options expiring December 12, 2034
Options underlying shares
150,000 shares
Exercise price $2.15 per share; expiration July 5, 2033
Exercise price
$2.15 per share
Options expiring July 5, 2033
Key Terms
restricted stock units, exercise price, Continuous Service, vest in full
4 terms
restricted stock units financial
"Represents restricted stock units granted on September 19, 2025"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"options at an exercise price of $0.5223"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Continuous Service technical
"subject to the Reporting Person's Continuous Service"
vest in full financial
"The options vest in full on November 12, 2027"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did CTOR director Suren G. Dutia receive?
Suren G. Dutia received options covering 125,000 common shares on November 12, 2026, at an exercise price of $0.5223 per share. They vest in full on November 12, 2027, subject to his Continuous Service to Citius Oncology or a related entity.
When do Suren G. Dutia’s CTOR restricted stock units vest?
The reported 300,000-share position represented by restricted stock units relates to units granted on September 19, 2025. They vest in full on the third anniversary of the grant date, subject to his Continuous Service to Citius Oncology or a related entity as of the vesting date.
What other options are listed for CTOR director Suren G. Dutia?
The report lists options covering 125,000 common shares at $1.07 per share, expiring December 12, 2034, and options covering 150,000 common shares at $2.15 per share, expiring July 5, 2033.
AI-generated analysis. How Rhea-AI works. Not financial advice.
